# Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

> **NCT03573700** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **St. Jude Children's Research Hospital** · enrollment: 24 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia, Refractory

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Mesna
- **DEVICE:** CliniMACS
- **BIOLOGICAL:** CD19- specific CAR engineered autologous T-cells (SJCAR19 product)

## Key facts

- **NCT ID:** NCT03573700
- **Lead sponsor:** St. Jude Children's Research Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-24
- **Primary completion:** 2023-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03573700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03573700, "Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT03573700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*